Cargando…

Baricitinib/lopinavir/ritonavir: Elevated transaminases and off-label use: case report

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453875/ http://dx.doi.org/10.1007/s40278-020-82605-3

Ejemplares similares

Lopinavir/ritonavir: Hyperlipidaemia following off-label use: case report
Publicado: (2020)

Lopinavir/ritonavir: Bradyarrhythmia following an off-label use : case report
Publicado: (2020)

Hydroxychloroquine/lopinavir/ritonavir: Bradycardia and off-label-use: case report
Publicado: (2021)

Lopinavir/ritonavir: Diarrhoea following off label use: case report
Publicado: (2021)

Lopinavir/ritonavir: Maculopapular rash following off-label use: case report
Publicado: (2020)

Lopinavir/ritonavir: Cardiotoxicities following off-label use: 4 case reports
Publicado: (2021)

Lopinavir/ritonavir: Nausea and vomiting following off label use: case report
Publicado: (2021)

Lopinavir/ritonavir: Hepatic cytolysis following off-label use: case report
Publicado: (2021)

Lopinavir/ritonavir: Lichen planus following off-label use: case report
Publicado: (2021)

Lopinavir/ritonavir/tocilizumab: Hypertriglyceridaemia following off-label use: 2 case reports
Publicado: (2020)

Lopinavir/ritonavir: Sick sinus syndrome following off-label use: case report
Publicado: (2020)

Lopinavir/ritonavir: Hepatobiliary disorder and hypertriglyceridaemia following off label use: case report
Publicado: (2021)

Ceftriaxone/levofloxacin/lopinavir/ritonavir: Thrombocytopenia following off-label use: case report
Publicado: (2021)

Lopinavir/ritonavir: Lack of efficacy following off-label use: 2 case reports
Publicado: (2022)

Hydroxychloroquine/lopinavir/ritonavir: Guillain-Barre-syndrome and off-label-use: case report
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Lack of efficacy and off label use: 3 case reports
Publicado: (2022)

Lopinavir/ritonavir/sirolimus interaction: Hepatitis following an off-label use: case report
Publicado: (2022)

Hydroxychloroquine/lopinavir/ritonavir: Lack of efficacy following off-label use: case report
Publicado: (2022)

Lopinavir/ritonavir: Third-degree atrioventricular block following off-label use: case report
Publicado: (2020)

Lopinavir/ritonavir: Worsening of liver injury following off-label use: 7 case reports
Publicado: (2020)

Lopinavir/ritonavir: Acute kidney injury following off-label use: 8 case reports
Publicado: (2020)

Lopinavir/ritonavir/rocuronium bromide interaction: Myopathy following off-label use: case report
Publicado: (2021)

Azithromycin/lopinavir/ritonavir: Acute kidney injury following off label use: case report
Publicado: (2021)

Ciclesonide/favipiravir/lopinavir/ritonavir: Off-label use, pancytopenia and liver dysfunction: case report
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir/tocilizumab: Lack of efficacy following off label use: case report
Publicado: (2022)

Lopinavir/ritonavir/ribavirin: Various toxicities following off-label treatment: case report
Publicado: (2020)

Lopinavir/ritonavir: Acute hepatocellular hepatitis following off-label use in COVID-19: case report
Publicado: (2020)

Lopinavir/ritonavir/remdesivir: Drug induced liver injury and off label use: 5 case reports
Publicado: (2020)

Lopinavir/ritonavir: Various toxicities following off-label use in COVID-19: 4 case reports
Publicado: (2021)

Lopinavir/ritonavir/umifenovir: Nausea, vomiting and diarrhoea following off-label treatment: case report
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir/methylprednisolone: Manic episode with psychotic features during an off-label use: case report
Publicado: (2020)

Azithromycin/hydroxychloroquine/lopinavir/ritonavir: Brugada-like ECG pattern following off-label use: case report
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Drug ineffectiveness following off-label use in COVID-19 infection: case report
Publicado: (2022)

Lopinavir/ritonavir: Diarrhoea, liver damage and loss of appetite during off-label treatment: case report
Publicado: (2020)

Multiple drugs: Elevated alanine transaminase and off label use: case report
Publicado: (2020)

Chloroquine/lopinavir/ritonavir/umifenovir: QTc interval prolongation, drug interaction and off-label use: 2 case reports
Publicado: (2020)

Lopinavir/ritonavir/immune globulin/interferon-α: Lack of efficacy during off-label treatment: case report
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Vomiting and QTc-interval prolongation following off-label therapy: 2 case reports
Publicado: (2021)

Azithromycin: Elevated transaminase levels during off-label treatment: case report
Publicado: (2021)

Lopinavir/ritonavir/oseltamivir/warfarin interaction: Increase in the INR and alanine aminotransferase following off label use: 10 case reports
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r5i2vao0j1t9k4aolc9jddr12m